← Back

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect against diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon to engineer precisely designed plasmid DNA, along with CELLECTRA smart device technology for delivery. The lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis, currently in Phase 1/2 trials. The pipeline includes VGX-3100 for HPV-related cervical high-grade squamous intraepithelial lesions, INO-3112 for HPV-related oropharyngeal squamous cell carcinoma (Phase 2), INO-5401 for glioblastoma multiforme (Phase 2), INO-4201 for Ebola virus disease (Phase 1b), INO-4800 for COVID-19 (Phase 2/3), and INO-6160 for HIV (Phase 1). Collaborators include ApolloBio Corporation, AstraZeneca, Coherus Biosciences, the Defense Advanced Research Projects Agency, the HIV Vaccines Trial Network, Kaneka Eurogentec, the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Price · split & dividend adjusted
News & notes moving 0A43.LSE
Biotech & Genomic Medicine

Precigen's Papzimeos Rakes In $74.6 Million in First Half of 2026

Precigen's sole marketed drug Papzimeos generated $74.6 million in revenues during the first six months of 2026, with second-quarter sales more than doubling sequentially. Papzimeos is the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, and management said demand continued to grow as the third quarter progressed. The company's marketing authorization application for Papzimeos in Europe is under review, and the drug holds seven years of FDA market exclusivity through Aug. 14, 2032. Rival Inovio Pharmaceuticals is developing INO-3107 for RRP, with an FDA decision expected on Oct. 30, 2026. Precigen also plans to update on its AdenoVerse portfolio, including PRGN-2009 in a phase II study with Merck's Keytruda, by the end of 2026.
PGEN ▲INO
Biotech & Genomic Medicine ▲
Zacks Investment Research·8dRead more →
Biotech & Genomic Medicine▲

Inovio Q2 2026 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported second quarter 2026 financial results and provided a regulatory update on its INO-3107 candidate for recurrent respiratory papillomatosis. The company's Biologics License Application for INO-3107 has a PDUFA target action date of October 30, 2026, with all scheduled prelicensure inspections completed and label negotiations expected to begin in September. Cash and cash equivalents were $36.7 million as of June 30, 2026, down from $58.5 million at the end of 2025, and a July equity offering added $18.3 million in net proceeds, extending the estimated cash runway into late first quarter 2027. Total operating expenses fell 19% year over year to $18.6 million, and the net loss narrowed to $6 million, or $0.07 per share, from $23.5 million, or $0.61 per share, a year earlier, driven in part by a $13.9 million noncash warrant liability gain. Management highlighted INO-3107's clinical efficacy, with the majority of Phase I/II trial participants experiencing a 50% to 100% reduction in surgery in the first year, and noted that competitor PAPZIMEOS had an 83% surgery rate in its Phase I/II trial.
INO ▲
Biotech & Genomic Medicine
The Motley Fool·37dRead more →
© 2026 MarketDXAsset